May 15 (Reuters) - vTv Therapeutics Inc VTVT.O:
VTV THERAPEUTICS ANNOUNCES REINITIATION OF SCREENING IN CATT1 PHASE 3 TRIAL EVALUATING POTENTIAL FIRST-IN-CLASS LIVER-SELECTIVE GLUCOKINASE ACTIVATOR CADISEGLIATIN FOR TYPE 1 DIABETES
VTV THERAPEUTICS INC - TOPLINE CATT1 PHASE 3 DATA EXPECTED IN 2H 2026
VTV THERAPEUTICS INC - PROTOCOL AMENDMENT SHORTENS TRIAL DURATION TO 6 MONTHS
Source text: ID:nGNX9tShQd
Further company coverage: VTVT.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。